Loading page content…
Loading page content…
Loading contract search results…
Loading contract details…
| Source: | Contracts Finder |
| Notice Type: | Award notice |
| Buyer: | East Sussex Healthcare NHS Trust |
| Main Category: | Services |
| Procurement Method: | Call-off from a framework agreement |
| Tender Status: | Closed |
| Estimated Value (ex. VAT): | £136,350 |
Awarded to
| Award value: | £272,700 |
| Award decision date: | 2 March 2026 |
| Award status: | Active |
Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient. Additional information: This is a call off contract from framework 2023/S 000-028831 based on previous contracts usage.
Published contracts in the last 12 months
58
total contracts
£22.6m
total value
£753,414
average contract size
Typical categories
Pipeline status
Not addedImports the contract into your BidWriter pipeline · Qualify before you commit to bid
Application Deadline
4 February 2026
Closed
Estimated Value
£136,350
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →| Release Date: | 3 March 2026 |
| Application Deadline: | 4 February 2026 |
| Contract Start Date: | 31 March 2026 |
| Contract End Date: | 31 March 2027 |
| Contract Duration: | 1.0 years |
| Procurement ID (OCID): | ocds-b5fd17-6952487a-f7d5-42df-ae7a-052feb2a20e7 |
| Notice Reference: | be83749f-55db-4eb4-b59b-40aa06ac75c4-886769 |
View Original Notice
Access the full notice on the official portal